TICK-BORNE ENCEPHALITIS VIRUS (EUROPEAN) NS1 PROTEIN

Tick-Borne Encephalitis Virus NS1 protein is produced entirely from human cell lines using state-of-the-art expression techniques, the same approach which NAC used to develop its well-received Dengue Virus NS1 serotypes and West Nile Virus NS1 protein.

The NAC Tick-Borne Encephalitis Virus NS1 protein has been manufactured in response to a need for a highly purified, concentrated protein for use in serological based diagnostic products. The antigen is in its native folding state, and possesses all post–translational modifications. This advanced approach results in a product which delivers optimal antigenicity due to its human origin.

PRODUCT DETAILS – TICK-BORNE ENCEPHALITIS VIRUS (EUROPEAN) NS1 PROTEIN

• Recombinant TBEV NS1 protein expressed from HEK293 cells (NCBI Accession Number: NP_043135.1).
• Includes amino acids 773-1128 and a C-terminal His-tag.
• Greater than 90% purity and buffered in DPBS pH 7.4, 0.2µm filter sterilised.

BACKGROUND

The Tick-borne encephalitis virus (TBEV) is a Flavivirus which is transmitted to humans through a bite from an infected tick. Tick-borne encephalitis (TBE) is endemic in Europe and Asia with an average of 8,500 cases per year in Europe (https://wwwnc.cdc.gov/travel/page/yellowbook-home-2014/). TBE infected patients typically present with influenza-like symptoms and the disease is neuroinvasive often manifesting as meningitis, encephalitis or meningoencephalitis. Long-lasting or permanent neuropsychiatric sequelae are reported in 10 to 20% of patients.

Tick-Borne Encephalitis Virus NS1 is presented in a hexameric state and as usual this product is produced to The Native Antigen Company’s very high quality standards for lot-to-lot variation minimisation and product traceability. Please see the downloadable Certificate of Analysis for more information.